Evidence map›Paper›PMID 25026173›Full record

ArticleInternational journal of molecular sciences2014

DADS suppresses human esophageal xenograft tumors through RAF/MEK/ERK and mitochondria-dependent pathways.

Xiaoran Yin, Jun Zhang, Xiaoning Li, Dong Liu, Cheng Feng, Rongrui Liang, Kun Zhuang, Chenlei Cai, Xinghuan Xue, Fuchun Jing and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Diallyl disulfide in oncotherapy: molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Molecular science for drug development and biomedicine.International journal of molecular sciences · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Xiaoran YinDepartment of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. yinxiaoran@163.com.
Jun ZhangDepartment of Digestion, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. jun3z@163.com.
Xiaoning LiDepartment of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. qingcao0066@163.com.
Dong LiuDepartment of Digestion, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. liudong_doc@163.com.
Cheng FengDepartment of Digestion, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. fc_2004188@163.com.
Rongrui LiangDepartment of Oncology, the First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou 215006, China. lengbeng@hotmail.com.
Kun ZhuangDepartment of Digestion, Xi'an Central Hospital, Xi'an 710003, China. zhuanger6695@sohu.com.
Chenlei CaiDepartment of Digestion, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. cchenlei2007@163.com.
Xinghuan XueDepartment of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. xuexinghuan1962@163.com.
Fuchun JingDepartment of Digestive Diseases, Baoji People's Hospital, Baoji 721000, China. fleming7798@163.com.
Xijing WangDepartment of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. wangxijingxian@126.com.
Jun WangDepartment of Gastroenterology, Xi'an Hospital of Traditional Chinese Medicine, Xi'an 710001, China. wangjuntaiji@126.com.
Xinlian LiuDepartment of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. liuxldoc@yeah.net.
Hongbing MaDepartment of Oncology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. mhbxian@126.com.
Second Affiliated Hospital of Xi'an Jiaotong University · CNBaoji City Central Hospital · CNFirst Affiliated Hospital of Soochow University · CNFirst Hospital of Xi'an · CNShaanxi Provincial Hospital of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diallyl disulfide (DADS) is a natural organosulfur compound isolated from garlic. DADS has various biological properties, including anticancer, antiangiogenic, and antioxidant effects. However, the anticancer mechanisms of DADS in human esophageal carcinoma have not been elucidated, especially in vivo. In this study, MTT assay showed that DADS significantly reduced cell viability in human esophageal carcinoma ECA109 cells, but was relatively less toxic in normal liver cells. The pro-apoptotic effect of DADS on ECA109 cells was detected by Annexin V-FITC/propidium iodide (PI) staining. Flow cytometry analysis showed that DADS promoted apoptosis in a dose-dependent manner and the apoptosis rate could be decreased by caspase-3 inhibitor Ac-DEVD-CHO. Xenograft study in nude mice showed that DADS treatment inhibited the growth of ECA109 tumor in both 20 and 40 mg/kg DADS groups without obvious side effects. DADS inhibited ECA109 tumor proliferation by down-regulating proliferation cell nuclear antigen (PCNA). DADS induced apoptosis by activating a mitochondria-dependent pathway with the executor of caspase-3, increasing p53 level and Bax/Bcl-2 ratio, and downregulating the RAF/MEK/ERK pathway in ECA109 xenograft tumosr. Based on studies in cell culture and animal models, the findings here indicate that DADS is an effective and safe anti-cancer agent for esophageal carcinoma.

Indexed as

Allyl CompoundsAnimalsAntineoplastic AgentsApoptosisbcl-2-Associated X ProteinCarcinomaCaspase 3Cell Line, TumorDisulfidesEsophageal NeoplasmsHumansMAP Kinase Signaling SystemMiceMice, NudeMitochondriaProliferating Cell Nuclear AntigenAllyl CompoundsAntineoplastic Agentsbcl-2-Associated X ProteinCaspase 3diallyl disulfideDisulfidesProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53

Identifiers

PMID25026173
PMCPMC4139851
OpenAlexW2066649636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.